Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Open Access

Brolucizumab for Treating Recalcitrant Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJan SpindlerIPIsabel B. PfisterAWA Weinberger

Discussion

Loading...

Member takes

Overview

Retrospective case series reports visual gains and increased treatment intervals in patients with recalcitrant neovascular AMD and PCV, indicating potential effectiveness of brolucizumab.

Key Points

  • Switching to brolucizumab improved treatment intervals from 5.6 to 10.5 weeks, enhancing patient management.
  • Among 27 eyes studied, 59.3% had recalcitrant AMD while 40.7% had PCV, showcasing significant disease variation.
  • The average central retinal thickness was notably lower in nAMD patients, highlighting differences in disease characteristics.
  • Despite the risk of intraocular inflammation, the drying potential of brolucizumab supports its application in resistant cases.

Cite This Study

Spindler et al. (2025) studied this question.

synapsesocial.com/papers/68c239a3b210217d6477cf03https://doi.org/10.21203/rs.3.rs-7357019/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Brolucizumab for Wet Age-related Macular Degeneration in Switch Patients: Long-Term Real-World Experience from a Tertiary Center2025
  2. 2Outcomes of Re-Switching Anti-vascular Endothelial Growth Factor After Brolucizumab-Associated Inflammation in Age-related macular degeneration2025
  3. 3Efficacy and Safety of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy: A Retrospective Cohort Study.2025
  4. 4Multimodal Imaging to Assess Disease Activity and Predict Fluid Resolution in Patients with wAMD Treated with Brolucizumab: The IMAGINE Study2025
  5. 5Retinal Occlusive Vasculitis after Intravitreal Brolucizumab Injection for Wet Age-related Macular Degeneration2025